Acer Therapeutics Develops Therapies for Patients with Serious, Ultra-Rare Diseases
Acer is a pharmaceutical company focused on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. Join us as we learn how they fulfill their company mission with largely a remote workforce.
Panelist: Tanya Hayden, Vice President of Project and Strategic Alliance Management for Acer Therapeutics.
Tanya Hayden joined Acer in June 2021 as Vice President of Project and Strategic Alliance Management.
During her nearly 20-year tenure at Lonza (formerly Bend Research/Capsugel), Ms. Hayden was responsible for oral drug delivery technologies, clinical and commercial contract manufacturing, operational excellence and client-focused project management. Throughout her career, Ms. Hayden has had the opportunity to lead internal cross-functional teams to introduce new capabilities and improve performance, as well as collaborate with external partners to advance new products to the market. Ms. Hayden received a B.S. degree in Chemistry from Gonzaga University.
Oregon Bio’s Makers & [bio] Markers is a fast-moving Zoomcast program that spotlights one of our member companies, or a service partner relevant to our bioscience community. Attendees are welcome to ask questions. It’s a quick and straight forward way for Oregon Bio members to learn a bit more about each other.
